This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Boston Scientific Corporation.SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease. Media Release: 20 May 2009. Available from: URL: http://www.bostonscientific.com
About this article
Cite this article
Percutaneous coronary intervention (PCI) using a paclitaxel-eluting stent system (TAXUS) is more cost effective than coronary bypass. Pharmacoecon. Outcomes News 579, 12 (2009). https://doi.org/10.2165/00151234-200905790-00028
- Coronary Artery Disease
- Coronary Artery
- Percutaneous Coronary Intervention
- Economic Analysis
- Medical Cost